Cite
HARVARD Citation
Walgaard, C. et al. (2021). Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet neurology. 20 (4), pp. 275-283. [Online].